HomeBusinessBiohaven Pharma Acquires Exclusive License for Oral, Brain-Penetrant, Dual TYK2/JAK1 Inhibitor for...

Biohaven Pharma Acquires Exclusive License for Oral, Brain-Penetrant, Dual TYK2/JAK1 Inhibitor for Immune-Mediated Brain Disorders

March 22, 2023

17

Biohaven Pharma Acquires Exclusive License for Oral, Brain-Penetrant, Dual TYK2/JAK1 Inhibitor for Immune-Mediated Brain Disorders

Source link

touristifier https://touristifier.com

LEAVE A REPLY Cancel reply

Please enter your comment!

Please enter your name here

You have entered an incorrect email address!

Please enter your email address here

Most Popular

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Functional

Performance

Analytics

Others

Biohaven Pharma Acquires Exclusive License for Oral, Brain-Penetrant, Dual TYK2/JAK1 Inhibitor for Immune-Mediated Brain Disorders

RBC lifts First Horizon stock target on strong quarter By Investing.com

Parsons secures spot on $225 million USACE contract By Investing.com

Bernstein raises LTTS stock target, keeps Underperform rating By Investing.com

LEAVE A REPLY Cancel reply

Most Popular

October 18 at T20 World Cup: West Indies take on New Zealand in a battle of underdogs

‘Consensus reached’ on establishment of constitutional bench

Texworld Apparel Sourcing Paris to host global suppliers in Feb 2025

RBC lifts First Horizon stock target on strong quarter By Investing.com

Recent Comments

EDITOR PICKS

October 18 at T20 World Cup: West Indies take on New...

‘Consensus reached’ on establishment of constitutional bench

Texworld Apparel Sourcing Paris to host global suppliers in Feb 2025

POPULAR POSTS

Matiullah Wesa: Taliban arrests prominent girls’ education activist in Afghanistan

Justice Department convinces federal judge Trump used his attorney in furtherance...

Watch: Finland’s PM Sanna Marin concedes election defeat

POPULAR CATEGORY